key: cord-0278047-tderrknp
authors: Liu, Shufeng; Chou, Chao-Kai; Wu, Wells W.; Luan, Binquan; Wang, Tony T.
title: Stable Cell Clones Harboring Self-Replicating SARS-CoV-2 RNAs for Drug Screen
date: 2021-11-08
journal: bioRxiv
DOI: 10.1101/2021.11.04.467291
sha: f40aadea09a23d9e7d9f3ed46ca5771b8ae7011b
doc_id: 278047
cord_uid: tderrknp

The development of antivirals against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been hampered by the lack of efficient cell-based replication systems that are amenable to high-throughput screens in biosafety level 2 laboratories. Here we report that stable cell clones harboring autonomously replicating SARS-CoV-2 RNAs without S, M, E genes can be efficiently derived from the baby hamster kidney (BHK-21) cell line when a pair of mutations were introduced into the non-structural protein 1 (Nsp1) of SARS-CoV-2 to ameliorate cellular toxicity associated with virus replication. In a proof-of-concept experiment we screened a 273-compound library using replicon cells and identified three compounds as novel inhibitors of SARS-CoV-2 replication. Altogether, this work establishes a robust, cell-based system for genetic and functional analyses of SARS-CoV-2 replication and for the development of antiviral drugs. IMPORTANCE SARS-CoV-2 replicon systems that have been reported up to date were unsuccessful in deriving stable cell lines harboring non-cytopathic replicons. The transient expression of viral sgmRNA or a reporter gene makes it impractical for industry-scale screening of large compound libraries using these systems. Here, for the first time, we derived stable cell clones harboring the SARS-CoV-2 replicon. These clones may now be conveniently cultured in a standard BSL-2 laboratory for high throughput screen of compound libraries. This achievement represents a ground-breaking discovery that will greatly accelerate the pace of developing treatments for COVID-19.

The single-stranded, positive-sense SARS-CoV-2 RNA genome is approximately 30 kb in length and comprises a short 5' untranslated region (UTR), 13 open reading frames (ORFs), a 3' UTR, and a poly(A) tail. Through discontinuous transcription events, the virus makes at least nine canonical subgenomic RNAs (sgmRNA), which encode structural and accessory proteins (1) . The genomic RNA (gRNA) harbors two large ORFs, ORF1a and ORF1ab, which are initially translated into two polyproteins, pp1a and pp1ab, and subsequently processed by viral proteases to produce 16 non-structural proteins (Nsp) that form the viral replication complex and confer immune evasion (2) (3) (4) .

Viral replication and translation machinery offer some of the most promising targets for antiviral drug development. For example, the main protease (Nsp 5) and the viral RNA-dependent RNA polymerase (Nsp 12) of SARS-CoV-2 are primary targets for antiviral discovery because they are responsible for cleavage of replicase polyproteins 1a/1ab and for virus replication, respectively. A cell-based system that harbors the minimally essential SARS-CoV-2 replication and translation machinery is highly desirable because it enables simultaneous screening of inhibitors of multiple viral proteins in a biosafety level 2 setting. To this end, subgenomic viral RNA molecules called replicons are often designed to autonomously replicate in cells without generating infectious virus. Current SARS-CoV-2 replicon systems, however, do not permit persistent replication in cell lines due to intrinsic toxicity (3, (5) (6) (7) (8) . The limited time window allowable for detection of replication, the inability to generate master and working cell banks for lot consistency, and the challenge to scale up for industrial processes, make it impractical to apply transient replicon systems in high-throughput screening (HTS) of large compound libraries. Here, we describe, for the first time, the derivatization and characterization of stable cell clones harboring autonomously replicating SARS-CoV-2 RNAs. We further demonstrated the applicability of cells harboring SARS-CoV-2 replicon RNA in drug screen.

To generate stable cell clones harboring replicating SARS-CoV-2 RNAs, we first constructed a replicon termed SARS-CoV-2-Rep-NanoLuc-Neo, in which the Spike (S) gene was replaced by a nanoluciferase reporter (NanoLuc), and the Envelope (E) and Membrane (M) genes were replaced with the neomycin phosphotransferase gene (Neo or NeoR) (Fig. 1A top panel) .

Electroporation of this replicon RNA along with in vitro transcribed RNA encoding the nucleocapsid protein (NP), which was previously shown to improve launch efficiency (9-11), into Vero E6, Huh7.5.1, A549 and BHK-21 cells resulted in expression of nanoluciferase to varying extents ( Fig. S1A-D) . However, no viable clones could be recovered after 21 days of selection in G418, suggesting that active replication of the replicon RNA is either unsustainable or cytotoxic. Huh7.5.1 and BHK-21 cells supported higher nanoluciferase expression than Vero E6 and A549, although we cannot rule out that the differences are attributed to different electroporation efficiency of the four cell lines. Because electroporating two different RNA species into the same cell is inefficient, we created a BHK-21 stable cell clone (BHK-21-NP Dox-ON ) in which NP is expressed in a doxycycline-inducible manner (Fig. S1E ). Electroporation of SARS-CoV-2-Rep-NanoLuc-Neo RNA into BHK-21-NP Dox-ON cells resulted in three neomycinresistant clones out of four million cells. The resulted clones grew very slowly in the presence of 200 µg/mL G418, and no nanoluciferase activity or viral RNA could be detected, indicating the loss of functional replicon RNA. Altogether, persistent replication of SARS-CoV-2-Rep-NanoLuc-Neo could not be achieved in any of the four mammalian cell lines.

Coronaviruses have evolved a variety of mechanisms to shut off host transcription and translation (12) (13) (14) . Of all SARS-CoV-2 proteins, Nsp1 causes the most severe viability reduction in cells of human lung origin (15) . The carboxyl terminus of Nsp1 folds into two helices, which insert into the mRNA entrance channel on the 40S ribosome subunit, preventing both the host mRNA and viral mRNA from gaining access to ribosomes and consequently shutting down translation (16, 17) (Fig 1.B) . The first C-terminal helix (residues 153-160) makes hydrophobic interactions with the 40S ribosomal protein uS5, and interacts with the 40S ribosomal protein uS3 with salt-bridges (e.g. D156-R143 and E159-K148); the second Cterminal helix (residues 166-178) interacts with ribosomal protein eS30 and with the phosphate backbone of h18 of the 18S rRNA via the two conserved arginines R171 and R175 (16) . In between the two helices, a conserved KH dipeptide (K164 and H165) forms critical interactions with h18 through H165 stacking between two uridines of 18S rRNA (U607 and U630), and electrostatic interactions between K164 and the phosphate backbone of rRNA bases G625 and U630 (Fig. 1C ). Molecular dynamics simulation followed by free energy perturbation calculation predicted that mutations of residues K164, R171, R175, H165, S167 of Nsp1 to alanine will reduce the interaction in the order of impact ( Fig. 1D and Fig. S2 ). We hypothesize that a pair of mutations, such as K164A/H165A that weaken the interaction between C-terminus of Nsp1 and ribosome, will lead to a shorter occupation time of Nsp1 on the ribosome and increase the accessibility of ribosomes to host mRNA. As a result, the Nsp1- (Table S1 ). It is worth mentioning that SARS-CoV-2-Rep-NanoLuc-Neo-Nsp1 K164A/H165A also replicated well in Huh7.5.1 cell line although no viable cells could be recovered after G418 selection (Fig. S3 ).

Moreover, we were able to derive at least 4 clones using standard BHK-21 cells albeit at much lower efficiency.

To explore the possibility for SARS-CoV-2-Rep-NanoLuc-Neo-Nsp1 K164A/H165A to persist in cells without selection pressure, G418 was subsequently withdrawn from Pool #1 cells after the initial selection. For up to one week there was no significant loss of nanoluciferase expression, a feature that is compatible with drug screen. The level of nanoluciferase decreased by one log after 10 days culturing without G418 and then by another two logs after 21 days ( Fig. 2A ).

Next, we performed quantitative reverse transcription PCR (RT-qPCR) to profile gRNA and sgmRNA species in cells harboring SARS-CoV-2-Rep-NanoLuc-Neo-Nsp1 K164A/H165A . SARS-CoV-2 transcribes multiple canonical sgmRNAs, including S, E, M, NP, ORF3a, ORF6, ORF7a, ORF7b, ORF8 and ORF10, although multiple studies have found negligible ORF10 expression and very few ORF7b body-leader junctions (1, 18) . In replicon cells, S, M, E sgmRNA are replaced with those encoding NanoLuc and NeoR; sgmRNA encoding ORF6 is lost because its transcriptional regulatory sequence body (TRS-B) resides in the M gene, which is also deleted in the replicon RNA. Hence, cells harboring the replicon would express at least six sgmRNAs, namely, Nanoluc, NeoR, ORF3a, ORF7a, ORF8, and NP. We designed primers/probes to specifically amplify the gRNA of the replicon and sgmRNAs of NanoLuc and NeoR. Shown in Fig. 2B and Fig. S4 , the temporal expression of gRNA and sgmRNA for the NanoLuc and NeoR genes were clearly observed in Pool #1 cells. Western blotting confirmed the presence of Nsp1 and NP in replicon cell lysates ( Fig. 2C and Fig. S4B ). To further characterize the replicon gRNA, next-generation sequencing (NGS) was performed on all 12 stable clones. While the replicon gRNA containing Nsp1 K164A/H165A was present in all clones, additional synonymous or missense mutations were detected in each clone (Table S2) . Among those, Nsp4 R401S substitution was detected in 10 out of 12 clones, and Nsp10 T111I appeared in 6 out of 12 clones. Ongoing research are studying whether if these changes constitute adaptive mutations which had enabled efficient replication in BHK-21 cells. Notably, sequencing the replicon gRNA in clone #9 also revealed a deletion knocking out ORF7a/b, ORF8 and the first 392 amino acids of the NP (Fig. S5) , indicating that NP is dispensable for genome replication. The presence of canonical sgmRNA species in each stable clone was also confirmed by NGS, although the method employed in this study could not locate all sgmRNA species due to uneven coverage of sequence reads over different regions (Fig. 2D ).

To demonstrate the suitability of SARS-CoV-2-Rep-NanoLuc-Neo-Nsp1 K164A/H165A cells in drug screen, we tested a library of 273 compounds for inhibitory effects. These compounds were selected to target Nsp5 (3CLpro), Nsp3 (PLpro), Nsp12 (RdRP), Nsp15, Nsp16, and X domain by virtual screen (Table S3) . At 10 µM, nine compounds exhibited more than 50% inhibition based on nanoluciferase expression (Fig. 3A ). Three compounds, Darapladib (predicted to target 3CLpro), Genz-123346 (predicted to target Nsp16), JNJ-5207852 (predicted to target Nsp15) (Fig. 3B ), were validated in replicon cells and then in three human cell lines A549-hACE2, Calu-3, Caco-2 cells using live virus. Remdesivir (inhibitor of RdRP) and GC376 (3CL protease inhibitor) were included as positive controls. The IC 50 of these compounds are provided in Figure 3C . Interestingly, all three compounds displayed cell type-specific activity against SARS-CoV-2, which others also noticed with repurposed drugs (19) . To further explore the robustness of replicon cells for drug screen, Remdesivir was added to Pool #1 cells on different days following G418 withdrawal. Cells were subsequently incubated for 2-7 days before nanoluciferase was quantified. We observed little difference in terms of the inhibitory strength when Remdesivir was added between 2 and 9 days following G418 withdrawal (Fig.   S6 ). By contrast, the optimal duration of Remdesivir treatment in replicon cells was between 3 and 6 days. Lastly, we sought to evaluate the clonal variability in response to drug treatment.

To this end, stable replicon cell clone #3, #5, #7, #9, #11 and #13 were tested for responses to GC376 treatment. Acquired IC 50 values ranged from 5.9 µM to 13 µM (mean = 9.3 µM, standard deviation = 2.9 µM), suggesting that all clones are potentially suitable for testing drug efficacy (Fig. 4) . (23) . Notably, as this manuscript was in preparation, a similar but non-identical SARS-CoV-2 replicon bearing Nsp1 K164A/H165A reportedly failed to generate stable cell clones in Huh-7.5 and BHK-21 cells (24), raising an interesting question whether the detected additional mutations from our stable cell clones facilitated non-cytopathic replication.

In summary, we have established a robust replicon system for future genetic and functional analyses of SARS-CoV-2 replication in vitro. To the best of our knowledge, this is the first time that stable cell clones harboring a SARS-CoV-2 replicon could be derived. These clones offer significant advantages over existing replicon systems in that cells may now be conveniently cultured, banked, qualified, and used in a standard BSL-2 laboratory for high throughput screen of compound libraries. This innovation will undoubtedly accelerate the pace of developing treatments for COVID-19.

The human kidney epithelial cell line Lenti-X 293T was purchased from Takara 

Doxycycline-inducible expression of SARS-CoV-2 NP was established in Vero E6, Huh7.5.1, and BHK-21 using TripZ-NP plasmid. NP cDNA was subcloned into pTripZ (AgeI/MluI) using the following primers: TripZ-NPf: 5'-ATATAGACCGGTCCACCATGTCTGATAATGGACCCCA-3', TripZ-NPr: 5'-ATATAGACGCGTTTAGGCCTGAGTTGAGTCAG-3'.

SARS-CoV-2 recombinant virus could be generated using a 7-plasmid reverse genetic system which was based on the virus strain (2019-nCoV/USA_WA1/2020) isolated from the first reported SARS-CoV-2 case in the U.S. (10) . The initial 7 plasmids were generous gifts from Dr. P-Y Shi (UTMB). Upon receipt, fragment 4 was subsequently subcloned into a low-copy plasmid pSMART LCAmp (Lucigen) to increase stability. Standard molecular biology technique was employed to create the SARS-CoV-2 nanoluciferase and firefly reporter viruses. In vitro transcription and electroporation were carried following procedures that were detailed elsewhere (25) .

The SARS-CoV-2-Rep-NanoLuc-Neo replicon was constructed based on the full-length SARS- The resulted plasmids were validated by restriction enzyme digestion and Sanger sequencing.

Assembly of the 7 plasmids into the replicon and in vitro transcription were performed following a published protocol (25) . For validation, A549-hACE2, Caco-2 or Calu-3 cells were seeded in 96-well plates at a density of 10 4 cells/well. Twenty-four hours later, cells were infected with SARS2-NanoLuc reporter virus in triplicates at an MOI of 0.05 in culture medium containing compounds. After 24 hours at 37 °C, cells were assayed for NanoLuc activity using Nano-Glo Luciferase Assay System or Luciferase Assay System (E1501, Promega).

To prepare sequencing libraries, 100 µl of total RNAs were extracted from 5 × 10 5 replicon cells using RNeasy mini kit (Qiagen, Gaithersburg, MD). 2 μ l of each sample was used to assess RNA quality using Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA), and the RNA integration numbers (RIN) were all greater than 9. A total of 300 ng of total RNA was used to prepare the sequencing library using Illumina Stranded Total RNA Prep, Ligation with Ribo-Zero Plus. After ribosomal RNA removal, adaptor ligation, and cDNA library concentration and normalization, prepared libraries were loaded onto a NextSeq sequencer Short, paired-end reads of RNA samples from 12 stable replicon cell clones were uploaded and analyzed on the NGS platform High performance Integrated Virtual Environment (HIVE) (26) . The reads were indexed, deduplicated, and quality metrics were collected upon data ingestion, which verified the high quality of the reads (Fig. S7) . Alignment of the reads were performed with HIVE's native (27) against the seven reference sequences. HIVE Hexagon default parameters, tuned for viral analysis allowing for small indels and mutations, were used and a threshold of 65 bases or longer of the aligned query was applied. Given the fact that the length of the reads was 70bp and the way the subject sequences were constructed, the alignments returned only split reads with patterns from both sides of the investigated junctions.

We carried out all-atom MD simulations for the complex of nsp1 and the fragment of rRNA (Charcoal gray in Fig. 1B) using the NAMD2.13 package (28) running on the IBM Power Cluster. The atomic coordinates for the complex (a bound state) were obtained from the crystal structure (PDB code: 7K5I) (20) . The complex was further solvated in a cubic water box that measures about 78×78×78 Å 3 . Na + and Cl − were added to neutralize the entire simulation system and set the ion concentration to be 0.15 M (Fig. S2A) . The final simulation system comprises 47,971 atoms. The built system was first minimized for 10 ps and then equilibrated for 1000 ps in the NPT ensemble (P ∼ 1 bar and T ∼ 300 K), with atoms in the backbones (of both nsp1 and RNA) harmonically restrained (spring constant k=1 kcal/mol/Å 2 ). The production run (∼200 ns) was performed in the NPT ensemble, when only constraining the terminals of nsp1 (both N-and C-terminals) and rRNA (both 5' and 3'-terminals). The same approach was applied in the production run for nsp1 in a 0.15 M NaCl electrolyte (Fig. S2B) , a free state required in the free energy perturbation (FEP) calculations (see below). The water box for the nsp1-only simulation also measures about 78×78×78 Å (29) . Note that the similar system size for the bound and free states are required for free energy perturbation calculations for mutations with a net charge change.

We used the CHARMM36m force field (29) for proteins and rRNA, the TIP3P model for water (30, 31) , the standard force field (32) for Na + and Cl − . The periodic boundary conditions (PBC) were applied in all three dimensions. Long-range Coulomb interactions were computed using particle-mesh Ewald (PME) full electrostatics with the grid size of about 1 Å in each dimension.

The pair-wise van der Waals (vdW) energies were calculated using a smooth (10-12 Å) cutoff.

The temperature T was kept at 300 K by applying the Langevin thermostat (33), while the pressure was maintained constant at 1 bar using the Nosé-Hoover method (34) . With the SETTLE algorithm (35) enabled to keep all bonds rigid, the simulation time-step was 2 fs for bonded and non-bonded (including vdW, angle, improper and dihedral) interactions, and the time-step for Coulomb interactions was 4 fs, with the multiple time-step algorithm (36) .

After equilibrating the structures in bound and free states, we performed free energy perturbation (FEP) calculations (37 (40, 41) .

Cytotoxicity was determined by cell viability assay as previously described. In brief, the cell viability was measured using Cell-Titer Glo (Promega) according to the manufacturers' instructions, and luminescence signals were measured by GloMax luminometer. CC 50 values were calculated using a nonlinear regression curve fit in Prism Software version 9 (GraphPad).

The reported CC 50 values were the results of at least 3 biological or technical replicates. Table S3 ) was screened in replicon cells (Pool #1) as described in Material and Method. Ten compounds (including Remdesivir) displayed more than 50% inhibition were denoted in black or colored solid circles. 

The Architecture of SARS-CoV-2 Transcriptome

The ORF8 protein of SARS-CoV-2 induced endoplasmic reticulum stress and mediated immune evasion by antagonizing production of interferon beta

Evasion of Type I Interferon by SARS-CoV-2

Activation and evasion of type I interferon responses by SARS-CoV-2

Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing

A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation

Construction of Noninfectious SARS-CoV-2 Replicons and Their Application in Drug Evaluation

A transcomplementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence

Rapid reconstruction of SARS-CoV-2 using a synthetic genomics platform

An Infectious cDNA Clone of SARS-CoV-2

SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract

SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis

A two-pronged strategy to suppress host protein synthesis by SARS coronavirus Nsp1 protein

Middle East Respiratory Syndrome Coronavirus nsp1 Inhibits Host Gene Expression by Selectively Targeting mRNAs Transcribed in the Nucleus while Sparing mRNAs of Cytoplasmic Origin

Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA

SARS-CoV-2 Nsp1 binds the ribosomal mRNA channel to inhibit translation

Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation

The coding capacity of SARS-CoV-2

Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2

SARS-CoV-2 Nsp1 suppresses host but not viral translation through a bipartite mechanism

Structure of the SARS-CoV-2 Nsp1/5'-Untranslated Region Complex and Implications for Potential Therapeutic Targets, a Vaccine, and Virulence

Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain

The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery

Replication and single-cycle delivery of SARS-CoV-2 replicons

Engineering SARS-CoV-2 using a reverse genetic system

High-performance integrated virtual environment (HIVE): a robust infrastructure for next-generation sequence data analysis

HIVE-hexagon: high-performance, parallelized sequence alignment for next-generation sequencing data analysis

Scalable molecular dynamics with NAMD

CHARMM36m: an improved force field for folded and intrinsically disordered proteins

Comparison of Simple Potential Functions for Simulating Liquid Water

Simulation of Activation Free Energies in Molecular Systems

Finite representation of an infinite bulk system: Solvent boundary potential for computer simulations

Computer Simulation of Liquids

Constant Pressure Molecular Dynamics Algorithms

SETTLE: An Analytical Version of the SHAKE and RATTLE Algorithm for Rigid Water Molecules

Reversible multiple time scale molecular dynamics

Free energy calculations

Free Energy of Ionic Hydration

Mechanism of Divalent-Ion-Induced Charge Inversion of Bacterial Membranes

Silico Antibody Mutagenesis for Optimizing Its Binding to Spike Protein of Severe Acute Respiratory Syndrome Coronavirus 2

Insights into SARS-CoV-2's Mutations for Evading Human Antibodies: Sacrifice and Survival

The authors are grateful to Dr. P-Y Shi (UTMB) who generously shared the 7-plasmid SARS-CoV-2 reverse genetics system. We thank Drs. K.